1. Moving to tolerance: clinical application of T regulatory cells.
- Author
-
McMurchy AN, Bushell A, Levings MK, and Wood KJ
- Subjects
- Animals, Chemotherapy, Adjuvant, Clinical Trials as Topic, Europe, Graft Rejection diagnosis, Graft Rejection prevention & control, Humans, Immunomodulation, T-Lymphocytes, Regulatory transplantation, Treatment Outcome, Cell- and Tissue-Based Therapy adverse effects, Cell- and Tissue-Based Therapy trends, Graft Rejection immunology, Organ Transplantation, T-Lymphocytes, Regulatory immunology, Transplantation Tolerance
- Abstract
Decreasing the incidence of chronic rejection and reducing the need for life-long immunosuppression remain important goals in clinical transplantation. In this article, we will review how regulatory T cells (Treg) came to be recognized as an attractive way to prevent or treat allograft rejection, the ways in which Treg can be manipulated or expanded in vivo, and the potential of in vitro expanded/generated Treg for cellular therapy. We will describe the first regulatory T cell therapies that have been or are in the process of being conducted in the clinic as well as the safety concerns of such therapies and how outcomes may be measured., (Copyright © 2011 Elsevier Ltd. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF